Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew I Milowsky

Showing results (181-190 of 205) with videos related to

Pageof 21
Sort By:
NPJ Precision Oncology|April 17, 2018
Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion moleculeMałgorzata A Witek, Rachel D Aufforth, Hong Wang, et al.
JAMA Oncology|November 1, 2019
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder CancerAndrea B Apolo, Matthew I Milowsky, Lauren Kim, et al.
European Urology|April 7, 2026
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 TrialMinas P Economides, Peter H O'Donnell, Ajjai S Alva, et al.
The Journal of Clinical Investigation|January 16, 2024
FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppressionAtsushi Okato, Takanobu Utsumi, Michela Ranieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerPeter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.
Clinical Genitourinary Cancer|March 23, 2017
Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter AnalysisAndrea Necchi, Gregory R Pond, Daniele Raggi, et al.
Clinical Genitourinary Cancer|March 10, 2020
Pilot Study of [<sup>18</sup>F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC)Patrick J Eulitt, Ersan Altun, Arif Sheikh, et al.
The New England Journal of Medicine|June 2, 2021
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial CarcinomaDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2017
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized StudyNeal D Shore, Stephen A Boorjian, Daniel J Canter, et al.
Future Oncology (London, England)|March 15, 2023
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summaryDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Pageof 21

Showing results (181-190 of 205) with videos related to

Sort By:
Pageof 21
NPJ Precision Oncology|April 17, 2018
Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion moleculeMałgorzata A Witek, Rachel D Aufforth, Hong Wang, et al.
JAMA Oncology|November 1, 2019
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder CancerAndrea B Apolo, Matthew I Milowsky, Lauren Kim, et al.
European Urology|April 7, 2026
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 TrialMinas P Economides, Peter H O'Donnell, Ajjai S Alva, et al.
The Journal of Clinical Investigation|January 16, 2024
FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppressionAtsushi Okato, Takanobu Utsumi, Michela Ranieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerPeter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.
Clinical Genitourinary Cancer|March 23, 2017
Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter AnalysisAndrea Necchi, Gregory R Pond, Daniele Raggi, et al.
Clinical Genitourinary Cancer|March 10, 2020
Pilot Study of [<sup>18</sup>F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC)Patrick J Eulitt, Ersan Altun, Arif Sheikh, et al.
The New England Journal of Medicine|June 2, 2021
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial CarcinomaDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2017
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized StudyNeal D Shore, Stephen A Boorjian, Daniel J Canter, et al.
Future Oncology (London, England)|March 15, 2023
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summaryDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Pageof 21